FIRST AMENDMENT OF LEASE AGREEMENTOf Lease Agreement • February 27th, 2018 • Endocyte Inc • Pharmaceutical preparations
THIS AGREEMENT is made and entered into this 10th day of November, 2017, by and between PURDUE RESEARCH FOUNDATION , an Indiana corporation (formed and existing under the Indiana Foundation or Holding Companies Act, Acts of 1921, ch. 246), (“Landlord”), and ENDOCYTE (“Tenant”). In consideration of their mutual promises contained in this Amendment, the parties agree as follows:
AMENDMENT #3 TO LICENSE AGREEMENT ID LA3190Endocyte Between Purdue Research Foundation and Endocyte, Inc.Confidential Treatment • February 27th, 2018 • Endocyte Inc • Pharmaceutical preparations
THIS AMENDMENT, made and entered into this 25th day of August 2017 (“Amendment Effective Date”) amends the Exclusive License Agreement (hereinafter AGREEMENT) between Purdue Research Foundation (hereinafter known as PRF) and Endocyte, Inc. (hereinafter known as LICENSEE) with an effective date of March 1, 2010.
AMENDMENT #20 TO LICENSE AGREEMENT ID LA0003Endocyte Between Purdue Research Foundation and Endocyte, Inc.Confidential Treatment • February 27th, 2018 • Endocyte Inc • Pharmaceutical preparations
THIS AMENDMENT, made and entered into this 25th day of August, 2017 (“Amendment Effective Date”) amends the Amended and Restated License Agreement executed on October 21st, 1998, and all subsequent Amendments (hereinafter AGREEMENT) between Purdue Research Foundation (hereinafter known as PRF) and Endocyte, Inc. (hereinafter known as LICENSEE).
AMENDMENT #9 TO LIENSE AGREEMENT ID 2014-0052 Between Purdue Research Foundation and Endocyte, Inc.Confidential Treatment • February 27th, 2018 • Endocyte Inc • Pharmaceutical preparations
THIS AMENDMENT, made and entered into this 25th day of August 2017 (“Amendment Effective Date”) amends the Master License Agreement entered into and effective as of July 1, 2013 and all subsequent Amendments (hereinafter “Agreement”) between Purdue Research Foundation (hereinafter known as “PRF”) and Endocyte, Inc. (hereinafter known as “Endocyte”) with respect to the matters addressed in this Agreement.
